Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$267.07+7.79 (+3.00%)
Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –
Ascendis Pharma A/S profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Ascendis Pharma A/S's profit margin for the twelve months ending Jun 30, 2026 was 70.8%. For fiscal 2025 it was -31.7%, against -104.0% the year before. The highest annual figure on record is -31.7% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -31.7% | +72.3 |
| FY2024 | Dec 31, 2024 | -104.0% | +76.5 |
| FY2023 | Dec 31, 2023 | -180.5% | +959.1 |
| FY2022 | Dec 31, 2022 | -1139.6% | +3791.9 |
| FY2021 | Dec 31, 2021 | -4931.6% | +1094.0 |
| FY2020 | Dec 31, 2020 | -6025.5% | −4395.5 |
| FY2019 | Dec 31, 2019 | -1630.0% | −400.5 |
| FY2018 | Dec 31, 2018 | -1229.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 61.0% | +85.6 |
| Q1 FY2026 | Mar 31, 2026 | 255.2% | +348.9 |
| Q4 FY2025 | Dec 31, 2025 | -13.6% | +8.6 |
| Q3 FY2025 | Sep 30, 2025 | -28.5% | +143.0 |
| Q2 FY2025 | Jun 30, 2025 | -24.6% | +279.3 |
| Q1 FY2025 | Mar 31, 2025 | -93.7% | +42.9 |
| Q4 FY2024 | Dec 31, 2024 | -22.1% | +41.0 |
| Q3 FY2024 | Sep 30, 2024 | -171.5% | +166.2 |
| Q2 FY2024 | Jun 30, 2024 | -303.9% | −47.6 |
| Q1 FY2024 | Mar 31, 2024 | -136.6% | +193.6 |
| Q4 FY2023 | Dec 31, 2023 | -63.1% | +842.8 |
| Q3 FY2023 | Sep 30, 2023 | -337.7% | +767.3 |
| Q2 FY2023 | Jun 30, 2023 | -256.2% | +1063.9 |
| Q1 FY2023 | Mar 31, 2023 | -330.2% | +1507.8 |
| Q4 FY2022 | Dec 31, 2022 | -905.9% | +1259.9 |
| Q3 FY2022 | Sep 30, 2022 | -1105.0% | +6114.0 |
| Q2 FY2022 | Jun 30, 2022 | -1320.1% | +11828.0 |
| Q1 FY2022 | Mar 31, 2022 | -1838.0% | +6579.2 |
| Q4 FY2021 | Dec 31, 2021 | -2165.9% | +23808.9 |
| Q3 FY2021 | Sep 30, 2021 | -7219.0% | −2803.3 |
| Q2 FY2021 | Jun 30, 2021 | -13148.1% | −6537.3 |
| Q1 FY2021 | Mar 31, 2021 | -8417.2% | −5571.5 |
| Q4 FY2020 | Dec 31, 2020 | -25974.8% | −22769.3 |
| Q3 FY2020 | Sep 30, 2020 | -4415.7% | −3296.1 |
| Q2 FY2020 | Jun 30, 2020 | -6610.9% | −4776.4 |
| Q1 FY2020 | Mar 31, 2020 | -2845.7% | – |
| Q4 FY2019 | Dec 31, 2019 | -3205.5% | – |
| Q3 FY2019 | Sep 30, 2019 | -1119.6% | – |
| Q2 FY2019 | Jun 30, 2019 | -1834.4% | – |
See a number that looks wrong?